The recommended concurrent chemotherapy regimens (cisplatin/paclitaxel and cisplatin/FU) in NCCN are based on BID fractionation of radiation as in RTO...
New comment by Radiation Oncologist at Dana-Farber Cancer Institute, Harvard Medical School ( September 23, 2021)
SWOG/NRG 1806, the currently accruing Phase III RCT of bladder-preserving trimodality therapy with vs without concurrent and adjuvant atezolizumab, allows (and stratifies by) ...